A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
对免疫检查点抑制剂有持久反应的晚期癌症患者的多机构生存研究
基本信息
- 批准号:10714336
- 负责人:
- 金额:$ 81.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-14 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptedAdvanced Malignant NeoplasmAgeBehavioralBiological MarkersBody CompositionCaliforniaCancer CenterCancer SurvivorshipCaringClinicalCommunitiesCompanionsComprehensive Cancer CenterDataDiagnosisDimensionsDiseaseDisease remissionDisseminated Malignant NeoplasmEnrollmentEthnic OriginEvidence based interventionFDA approvedHealth behaviorImmune checkpoint inhibitorImmune responseImmunotherapeutic agentImmunotherapyIn complete remissionInferiorInfusion proceduresInterventionLearningLife StyleLongitudinal StudiesMalignant NeoplasmsMalignant neoplasm of lungMetastatic MelanomaModelingMutationPatient CarePatient Outcomes AssessmentsPatientsPhasePopulationPredictive FactorPreparationPrognosisProgression-Free SurvivalsProspective cohortPsychosocial FactorQuality of lifeRaceRenal carcinomaSisterSurvivorsSymptomsTelomere Length MaintenanceTherapeuticUniversitiesUnresectableadvanced diseasebehavioral healthcancer diagnosiscancer immunotherapycancer therapycancer typecheckpoint therapyclinical practiceclinical predictorscohortdemographicsdesignfollow-upimprovedipilimumabmelanomapartial responsepatient populationpredictive markerprogrammed cell death ligand 1psychosocialpsychosocial wellbeingracial disparityresponsesexside effectsurvival predictionsurvivorshiptumor
项目摘要
ABSTRACT
Immune checkpoint inhibitors (ICIs) have markedly transformed the therapeutic landscape for many types of
advanced malignancies over the past decade. A sizable proportion of patients with advanced cancer derive
durable benefits from ICIs and achieve longer periods of progression-free survival or remission than previously
possible. Yet we still know little about the determinants of durable response to ICI treatment and the symptom
trajectory and survivorship needs of this growing patient population. We thus propose a multi-institute study
with two sister cohorts of patients living with advanced cancers. First, a retrospective EHR data-only cohort will
include 8,860 patients with advanced disease, inclusive of all cancer types, who have been treated with ICI-
based immunotherapy in 2014-2022. This large cohort will allow us to identify and study durable responders to
ICIs, defined as patients who achieve partial or complete response to ICI treatment and live at least one year
after ICI treatment initiation. Second, a prospective cohort will enroll and actively follow an estimated 1,200
patients with durable response to ICI treatment for advanced lung cancer, kidney cancer, and melanoma, the
three most common cancers treated with ICIs. Clinical and patient-reported outcome data will be collected at
baseline and every 6 months during follow up. This prospective cohort will allow us to study long-term survival
and physical and psychosocial symptom trajectories in patients with durable response to ICIs, and to identify
clinical and modifiable behavioral factors predictive of long-term survival and common side effects of ICI
treatment. The predictors identified in these analyses will be independently validated in the DiRECT Cohort, a
large ongoing study of racial disparities in ICI treatment led by the study team. Our Specific Aims are:
1. In the retrospective EHR data-only cohort, 1a) Determine the proportion of patients who had durable
response to ICI treatment (partial/complete response and alive ≥1 year since initial ICI treatment) and chart
their survival trajectory; 1b) Identify clinical predictors for durable response to ICI treatment; 1c). In the
independent DiRECT Cohort, validate the clinical predictors for durable response to ICI treatment.
2. In the prospective cohort, 2a) Identify long-term survival and longitudinal trajectories of patients' physical
and psychosocial symptoms after ICI treatment; 2b) Investigate the relationships of long-term survival and
common side effects from ICI treatment with multidimensional predictors; 2c). In the independent DiRECT
Cohort, validate the predictors for survival and common side effects in patients with durable response.
Findings from our study will provide much-needed data that can inform new evidence-based intervention
strategies as the next step to optimize survivorship care and extend and improve quality of life for the growing
population of survivors living after a diagnosis of advanced cancer due to ICI treatment.
摘要
免疫检查点抑制剂(ICI)已经显著改变了许多类型的免疫缺陷的治疗前景。
在过去十年中,晚期恶性肿瘤。相当大比例的晚期癌症患者
ICIs的持久获益,并实现比以前更长的无进展生存期或缓解期
可能然而,我们对ICI治疗的持久反应的决定因素和症状仍然知之甚少。
这一不断增长的患者群体的轨迹和生存需求。因此,我们建议进行多机构研究
与两组晚期癌症患者的姐妹队列进行比较。首先,一个回顾性的EHR数据队列将
包括8,860名晚期疾病患者,包括所有癌症类型,他们接受了ICI治疗,
2014-2022年的免疫治疗。这个大的队列将使我们能够识别和研究持久的反应者,
ICI,定义为对ICI治疗达到部分或完全缓解且存活至少1年的患者
ICI治疗开始后。第二,一个前瞻性队列将招募并积极随访估计1,200名
对ICI治疗晚期肺癌、肾癌和黑色素瘤有持久反应的患者,
三种最常见的用ICIs治疗的癌症临床和患者报告的结局数据将在
基线和随访期间每6个月。这个前瞻性队列将使我们能够研究长期生存率
以及对ICI有持久反应的患者的身体和心理社会症状轨迹,并确定
预测ICI长期生存和常见副作用的临床和可改变的行为因素
治疗这些分析中确定的预测因子将在DireCT队列中独立验证,
由研究小组领导的关于ICI治疗中种族差异的大型正在进行的研究。我们的具体目标是:
1.在仅回顾性EHR数据队列中,1a)确定具有持久性
对ICI治疗的应答(部分/完全应答,自初始ICI治疗后存活≥1年)和图表
它们的生存轨迹; 1b)确定对ICI治疗的持久反应的临床预测因子; 1c).在
独立的DireCT队列,验证ICI治疗持久应答的临床预测因子。
2.在前瞻性队列中,2a)确定患者的长期生存和身体状况的纵向轨迹
ICI治疗后的心理社会症状; 2b)研究长期生存和
ICI治疗的常见副作用与多维预测因子; 2c)。在独立的Direct
队列研究,验证持久缓解患者的生存和常见副作用的预测因子。
我们的研究结果将提供急需的数据,为新的循证干预提供信息。
战略作为下一步,以优化生存护理,延长和提高生活质量的增长
由于ICI治疗而诊断为晚期癌症后生活的幸存者人群。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Stewart Kamen其他文献
Charles Stewart Kamen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Stewart Kamen', 18)}}的其他基金
The Science of Cancer Health Equity for Sexual and Gender Minority Communities
性和性别少数群体的癌症健康公平科学
- 批准号:
10749970 - 财政年份:2023
- 资助金额:
$ 81.59万 - 项目类别:
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
免疫检查点抑制剂治疗 (DiRECT) 结果的差异:在社区肿瘤学环境中接受抗 PD-1/抗 PD-L1 治疗的癌症幸存者的前瞻性队列研究
- 批准号:
10220449 - 财政年份:2021
- 资助金额:
$ 81.59万 - 项目类别:
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
免疫检查点抑制剂治疗 (DiRECT) 结果的差异:在社区肿瘤学环境中接受抗 PD-1/抗 PD-L1 治疗的癌症幸存者的前瞻性队列研究
- 批准号:
10883853 - 财政年份:2021
- 资助金额:
$ 81.59万 - 项目类别:
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
免疫检查点抑制剂治疗 (DiRECT) 结果的差异:在社区肿瘤学环境中接受抗 PD-1/抗 PD-L1 治疗的癌症幸存者的前瞻性队列研究
- 批准号:
10391553 - 财政年份:2021
- 资助金额:
$ 81.59万 - 项目类别:
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors
针对女同性恋、男同性恋、双性恋和变性癌症幸存者的运动干预
- 批准号:
9512855 - 财政年份:2015
- 资助金额:
$ 81.59万 - 项目类别:
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors
针对女同性恋、男同性恋、双性恋和变性癌症幸存者的运动干预
- 批准号:
9112953 - 财政年份:2015
- 资助金额:
$ 81.59万 - 项目类别:
相似海外基金
How novices write code: discovering best practices and how they can be adopted
新手如何编写代码:发现最佳实践以及如何采用它们
- 批准号:
2315783 - 财政年份:2023
- 资助金额:
$ 81.59万 - 项目类别:
Standard Grant
One or Several Mothers: The Adopted Child as Critical and Clinical Subject
一位或多位母亲:收养的孩子作为关键和临床对象
- 批准号:
2719534 - 财政年份:2022
- 资助金额:
$ 81.59万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633211 - 财政年份:2020
- 资助金额:
$ 81.59万 - 项目类别:
Studentship
A material investigation of the ceramic shards excavated from the Omuro Ninsei kiln site: Production techniques adopted by Nonomura Ninsei.
对大室仁清窑遗址出土的陶瓷碎片进行材质调查:野野村仁清采用的生产技术。
- 批准号:
20K01113 - 财政年份:2020
- 资助金额:
$ 81.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2436895 - 财政年份:2020
- 资助金额:
$ 81.59万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633207 - 财政年份:2020
- 资助金额:
$ 81.59万 - 项目类别:
Studentship
The limits of development: State structural policy, comparing systems adopted in two European mountain regions (1945-1989)
发展的限制:国家结构政策,比较欧洲两个山区采用的制度(1945-1989)
- 批准号:
426559561 - 财政年份:2019
- 资助金额:
$ 81.59万 - 项目类别:
Research Grants
Securing a Sense of Safety for Adopted Children in Middle Childhood
确保被收养儿童的中期安全感
- 批准号:
2236701 - 财政年份:2019
- 资助金额:
$ 81.59万 - 项目类别:
Studentship
A Study on Mutual Funds Adopted for Individual Defined Contribution Pension Plans
个人设定缴存养老金计划采用共同基金的研究
- 批准号:
19K01745 - 财政年份:2019
- 资助金额:
$ 81.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and functional analyses of a bacterial protein translocation domain that has adopted diverse pathogenic effector functions within host cells
对宿主细胞内采用多种致病效应功能的细菌蛋白易位结构域进行结构和功能分析
- 批准号:
415543446 - 财政年份:2019
- 资助金额:
$ 81.59万 - 项目类别:
Research Fellowships